From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesHonvan, Difostilben, Fosfostilben, Fostrolin, Stilbol, Stilphostrol, Vagestrol
SynonymsDiethylstilbestrol diphosphate; Stilbestrol diphosphate; DESDP; DESP
AHFS/Drugs.comInternational Drug Names
Routes of
Intramuscular injection
Drug classNonsteroidal estrogen; Estrogen ester
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
CAS Number
PubChem CID
ECHA InfoCard100.007.573 Edit this at Wikidata
Chemical and physical data
Molar mass428.310 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fosfestrol (INN, BAN, JAN) (brand names Honvan, Difostilben, Fosfostilben, Fostrolin, Stilbol, Stilphostrol, Vagestrol, among others), also known as diethylstilbestrol diphosphate (USAN), abbreviated as DESDP or DESP, is a synthetic nonsteroidal estrogen of the stilbestrol group which is or has been used in the treatment of prostate cancer.[1][2] It is a prodrug of diethylstilbestrol.[3] The drug has been marketed widely throughout the world, including in the United States, Canada, Europe, Hong Kong, and Mexico.[1]

Fosfestrol has been used to prevent the testosterone flare at the start of gonadotropin-releasing hormone agonist therapy in men with prostate cancer.[4]

See also[edit]


  1. ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 332–. ISBN 978-3-88763-075-1.
  2. ^ Shanbhag (1 January 2008). Pharmacology: Prep Manual for Undergraduates. Elsevier India. pp. 463–. ISBN 978-81-312-1153-3.
  3. ^ Urotext (1 January 2001). Urotext-Luts: Urology. Urotext. pp. 386–. ISBN 978-1-903737-03-3.
  4. ^ Kotake T, Usami M, Akaza H, Koiso K, Homma Y, Kawabe K, Aso Y, Orikasa S, Shimazaki J, Isaka S, Yoshida O, Hirao Y, Okajima E, Naito S, Kumazawa J, Kanetake H, Saito Y, Ohi Y, Ohashi Y (November 1999). "Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group". Jpn. J. Clin. Oncol. 29 (11): 562–70. doi:10.1093/jjco/29.11.562. PMID 10678560.